Código QR

Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants

As new SARS-CoV-2 variants continue to emerge, it is important to evaluate the potency of antiviral drugs to support their continued use. Remdesivir (RDV; VEKLURY<sup>®</sup>) an approved antiviral treatment for COVID-19, and obeldesivir (ODV) are inhibitors of the SARS-CoV-2 RNA-dependent RNA polym...

Descrición completa

Gardado en:
Principais autores: Lauren Rodriguez, J. Lizbeth Reyes Zamora, Dong Han, Jasmine Moshiri, Nadine Peinovich, Clarissa Martinez, Pui Yan Ho, Jiani Li, Thomas Aeschbacher, Ross Martin, Andrew Pekosz, John P. Bilello, Jason K. Perry, Charlotte Hedskog
Formato: Artigo
Idioma:Inglês
Publicado: MDPI AG 2025-01-01
Series:Viruses
Assuntos:
SARS-CoV-2
COVID-19
Omicron variants
remdesivir
genotyping
phenotyping
Acceso en liña:https://www.mdpi.com/1999-4915/17/2/168
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares